Instruction for use: Carsil

Active substance Silybi mariani fructuum extract

ATX code A05BA03 Silymarin

Pharmacological group

Hepatoprotectors

Nosological classification (ICD-10)

B94.2 Long-term effects of viral hepatitis

K70 Alcoholic liver disease

Cirrhosis of alcoholic origin, Alcoholic liver damage, Alcoholic liver damage, Liver diseases of alcoholic etiology,Alcohol Hepatopathy

K70.0 Alcoholic fatty liver [fatty liver]

Alcohol steatohepatitis, Fatty degeneration of the liver of alcoholic origin, Steatosis

K71 Toxic liver disease

Toxic liver damage, Hepatitis medication, Hepatitis Toxicum, Liver medication, Medicinal Hepatitis, Liver medications, Medicinal Hepatitis, , Dysfunction of the liver of toxic etiology, Toxic hepatitis, Toxic liver damage, Toxic hepatitis, Hepatotoxic effect of drugs, Toxic liver disease, Effect of drugs on the liver, The effect of toxins on the liver

K73.9 Chronic hepatitis, unspecified

Chronic hepatitis, Chronic hepatitis with signs of cholestasis, Inflammatory liver disease, Infection of the liver, Chronic reactive hepatitis, Chronic inflammatory liver disease, Hepatitis chronic

K74 Fibrosis and cirrhosis of the liver

Otecno-ascitic syndrome with cirrhosis of the liver, Inflammatory liver disease, Precircrotic condition, Cystic fibrosis of the liver, Cirrhotic and precircotic state, Cirrhosis with portal hypertension, Cirrhosis of the liver with portal hypertension and edematous-ascitic syndrome, Cirrhosis of the liver with portal hypertension, Cirrhosis of the liver with ascites and edema, Cirrhosis of the liver with ascites, Cirrhotic ascites

K76.0 Fatty liver degeneration, not elsewhere classified

Fatty hepatosis, Hepatosis fat, Dystrophy of fatty liver, Fatty liver infiltration, Fatty liver degeneration, Fatty degeneration of the liver, Steathepatitis, Fatty degeneration of the liver, Non-alcoholic steatohepatitis, Disorders of lipid metabolism of the liver, Steatosis, Steatosis states, Lipidoses, Acute yellow atrophy of the liver

K76.9 Liver disease, unspecified

Change in liver function in heart failure, Restoration of impaired liver function, Severe liver function disorders, Hepatitis, Hepatosis, Hepatopathy, Liver dysfunction, Diseases of the liver, Impaired liver function, Dysfunction of the liver, Infringements of function of a liver of an inflammatory etiology, Functional liver failure, Functional disorders of the liver, Chronic liver disease, Chronic diffuse liver disease, Enterogenic diseases of the gallbladder and liver

T50.9 Other and unspecified drugs, medicines and biological substances

Poisoning by cauterizing fluidsá Correction of side effects of drugs, Drug intoxication, Medication intoxication, Acute drug poisoning, Acute drug poisoning, Acute poisoning with potent and toxic substances, Poisoning with medicines, Oxalate poisoning, Poisoning by potent and poisonous substances, Poisoning with iodine preparations

T51 Toxic effect of alcohol

Intoxication alcoholic, Alcohol intoxication, Intoxication with alcohol, Acute alcohol intoxication, Chronic alcohol intoxication

T65.9 Toxic effect of unspecified substance

idiosyncrasy toxic, Intoxication nitro compounds, Intoxication toxins, Professional intoxication, Poisoning nitrites, Poisoning toxins

Y57 Adverse reactions in the therapeutic use of other and unspecified drugs and medications

Z57 Occupational exposure to risk factors

The impact of chemical factors, The adverse effect of occupational risk factors, The adverse effect of occupational risk factors, Work in extreme professional loads, Work in harmful conditions, Work in hazardous industries, Working with occupational risk factors, Occupational lung diseases

Composition

Bean 1 Bean

active substance:

Milk thistle fruit extract dry (equivalent silymarin) 35 mg

Excipients

core: lactose monohydrate - 55.38 mg; wheat starch - 55.38; Povidone (Kollidon 25) - 1.65 mg; MCC - 67 mg; magnesium stearate - 2.5 mg; talc - 7 mg; dextrose monohydrate - 20.6 mg; sorbitol - 4.13 mg; sodium bicarbonate - 1.36 mg

sheath: cellulose phosphate - 0.84 mg; diethyl phthalate - 0.6 mg; sucrose - 162.19 mg; acacia gum - 1,562 mg; gelatin - 0.86 mg; talc - 26.718 mg; titanium dioxide - 4.82 mg; macrogol (PEG 6000) - 0.13 mg; Brown Opalux dye (sucrose, ferric oxide red, ferric oxide black, methyl and propyl parahydroxybenzoate, purified water) - 2.25 mg; glycerol - 0.03 mg

pharmachologic effect

Pharmacological action - hepatoprotective.

Dosage and administration

Inside

Take before meals with plenty of water.

The duration of treatment is at least 3 months.

Adults and children over 12 years of age: treatment of severe liver damage starts with a daily dose of 420 mg (4 pills 3 times a day). In milder cases and as maintenance therapy, 1-2 pills 3 times a day.

Prophylactically take 2-3 pills per day.

Release form

Dragee, 35 mg. In blisters of PVC film and aluminum foil, 10 pcs .; in a pack of cardboard 8 or 18 bl.

Pharmacy sales terms

Over the counter.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf Life

2 years.

Do not use after the expiration date printed on the package.